Leading Clinical Innovation in Metabolic Stability

Mount BioTherapeutics specializes in next-generation long-acting amylin receptor antagonists engineered with our proprietary Dual-Shield™ technology to address obesity and Type 2 Diabetes effectively.

Advanced Dual-Shield™ Technology Platform

Our patented Dual-Shield™ platform enhances drug stability and efficacy by integrating innovative molecular architectures designed for prolonged action in metabolic disease treatments. This approach aims to maximize therapeutic benefits while minimizing dosing frequency.

2

Patent Applications Pending

2

Lead Candidates in Clinical Stage

10+

Years of R&D Expertise

Proprietary Dual-Shield™ Platform

A unique molecular design that significantly improves metabolic stability and therapeutic duration.

Focused Pipeline Development

Lead candidates MBT-101 and MBT-102 targeting obesity and Type 2 Diabetes with patent-pending status.

Clinical-Stage Validation

Rigorous clinical evaluation ensuring    advanced safety and efficacy profiles.

Strategic Innovation Team

Experienced biotech professionals   steering focused research and development efforts.

I hereby agree that this data will be stored and processed for the purpose of establishing contact. I am aware that I can revoke my consent at any time.*

*Please fill in all the required fields.
Message was successfully sent

Get in touch

Telephone:

E-mail:

Address:

©Copyright. All rights reserved.

We need your consent to load the translations

We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.